Kazia Therapeutics Limited (KZIA) Income Statement
KZIA FY2025 at a glance
Fiscal year ended June 30, 2025 · Australian dollarsKZIA revenue and net income
Where KZIA's revenue goes
FY2025Each bar shows an amount and its share of revenue. KZIA kept −49,290.5% of revenue as net income.
KZIA profit margins
KZIA growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −98.2% | +61.3% | −46.8% | −7.2% |
| Gross profit | −98.2% | +61.3% | −46.8% | −7.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KZIA income statement in Australian dollars
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$42,000 | A$2.3M | A$555 | A$10,000 | A$15.2M | A$988,110 | A$1,565 | A$13,108 | A$8.8M | A$4.1M |
| Cost of revenue | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Gross profit | A$42,000 | A$2.3M | A$555 | A$10,000 | A$15.2M | A$988,110 | A$1,565 | A$13,108 | A$8.8M | A$4.1M |
| Research & development | A$7.3M | A$17.4M | A$15.6M | A$20.2M | A$14.5M | A$9.5M | A$6.5M | A$9.8M | A$11.1M | A$9.9M |
| Sales, general & admin | A$8.7M | A$13.6M | A$8.6M | A$5.2M | A$7.0M | A$3.7M | A$3.8M | A$5.6M | A$8.5M | A$5.8M |
| Total operating expenses | A$14.3M | A$30.8M | A$24.1M | A$25.4M | A$21.6M | A$13.2M | A$10.3M | A$14.7M | A$19.7M | A$15.6M |
| Operating income | −A$14.2M | −A$28.5M | −A$24.1M | −A$25.4M | −A$6.4M | −A$12.2M | −A$8.4M | −A$12.5M | −A$10.9M | −A$12.8M |
| Interest income | A$72,000 | A$12,000 | A$22,558 | A$2,094 | A$42,000 | A$66,000 | A$100,000 | A$119,000 | A$249,000 | A$40 |
| Interest expense | — | — | — | A$2,094 | A$5.1M | A$240,000 | A$2.2M | A$0 | A$765,000 | A$0 |
| Income before taxes | −A$22.4M | −A$27.0M | −A$20.7M | −A$25.4M | −A$8.9M | −A$12.8M | −A$10.6M | −A$6.3M | −A$10.9M | −A$12.2M |
| Income taxes | −A$1.7M | −A$271,000 | −A$271,092 | −A$368,000 | −A$484,000 | −A$298,195 | −A$298,000 | −A$305,000 | −A$198,544 | A$2.8M |
| Net income | −A$20.7M | −A$26.8M | −A$20.5M | −A$25.0M | −A$8.4M | −A$12.5M | −A$10.3M | −A$6.0M | −A$10.7M | −A$12.1M |
| EBITDA | −A$13.3M | −A$26.6M | −A$22.3M | −A$23.5M | −A$5.1M | −A$11.1M | −A$7.7M | −A$13.0M | −A$9.4M | −A$11.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −33,850.0% | −1,233.2% | −4,346,661.1% | −253,990.0% | −42.0% | −1,234.3% | −535,463.3% | −95,262.4% | −123.5% | −313.7% |
| Net margin | −49,290.5% | −1,160.2% | −3,687,419.8% | −250,140.0% | −55.5% | −1,261.7% | −656,230.0% | −46,071.1% | −121.4% | −296.3% |
| Dec '25 | Sep '25 | Dec '24 | Sep '24 | Dec '23 | Sep '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$0 | A$19,710 | A$22,290 | A$2.5M | A$5 | A$1,000 | A$278 | A$0 | A$0 | A$0 | A$0 | A$10,000 |
| Cost of revenue | — | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$626,204 | A$2.9M | — | — | A$0 |
| Gross profit | — | A$19,710 | A$22,290 | A$2.5M | A$5 | A$1,000 | A$278 | −A$626,204 | −A$671,826 | — | — | A$10,000 |
| Research & development | A$4.9M | A$3.0M | A$4.3M | A$13.1M | A$4.3M | A$6.2M | A$3.1M | A$9.4M | A$9.2M | A$4.7M | A$4.6M | A$11.0M |
| Sales, general & admin | — | — | A$5.1M | A$9.0M | A$4.6M | A$4.3M | A$2.2M | A$4.3M | A$2.8M | A$2.1M | A$1.4M | A$2.5M |
| Total operating expenses | A$13.3M | A$6.5M | A$9.4M | A$22.1M | A$8.9M | A$10.5M | A$3.5M | A$13.6M | A$25.4M | A$6.9M | A$5.9M | A$13.5M |
| Operating income | −A$13.3M | −A$4.8M | −A$9.4M | −A$19.6M | −A$8.9M | −A$10.5M | −A$5.3M | −A$13.6M | −A$25.4M | −A$6.8M | −A$6.0M | −A$13.5M |
| Interest expense | — | — | — | — | — | — | — | — | A$4.4M | — | — | — |
| Income before taxes | −A$12.3M | −A$11.9M | −A$10.6M | −A$18.1M | −A$9.0M | −A$7.0M | −A$3.5M | −A$13.7M | −A$11.9M | −A$6.9M | −A$5.9M | −A$13.5M |
| Income taxes | — | −A$1.6M | −A$135,546 | −A$135,454 | −A$135,546 | −A$135,454 | A$67,773 | −A$135,546 | −A$52,106 | A$67,773 | A$26,053 | −A$315,974 |
| Net income | −A$12.3M | −A$10.0M | −A$10.5M | −A$18.0M | −A$8.8M | −A$6.9M | −A$3.4M | −A$13.6M | −A$11.8M | −A$6.8M | −A$5.9M | −A$13.2M |
| EBITDA | −A$13.3M | −A$4.8M | −A$8.9M | −A$18.6M | −A$7.9M | −A$9.6M | −A$4.8M | −A$12.7M | −A$11.0M | −A$6.4M | −A$5.5M | −A$12.5M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | 100.0% |
| Operating margin | — | −24,599.8% | −42,029.5% | −789.1% | −177,668,060.0% | −1,050,951.4% | −1,890,295.3% | — | — | — | — | −134,606.6% |
| Net margin | — | −50,487.2% | −46,899.1% | −723.7% | −176,470,260.0% | −687,897.3% | −1,237,257.6% | — | — | — | — | −132,018.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported in KZIA's financial statements (latest annual report filed November 7, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KZIA financial results
In fiscal year 2025 (ended June 30, 2025), Kazia Therapeutics reported revenue of A$0.0 million, down 98.2% from the year before. It had a net loss of A$20.7 million, a net profit margin of −49,290.5%. Over five years revenue grew at an average rate of −46.8% a year. Figures are in Australian dollars, the currency of its financial statements.
See the KZIA stock overview for the latest quote and news, or the KZIA chart for price history and technical indicators.
KZIA income statement FAQ
What is Kazia Therapeutics's annual revenue?
Kazia Therapeutics reported total revenue of A$0.0 million for fiscal year 2025, which ended on June 30, 2025. That was down 98.2% from A$2.3 million the previous year.
Is Kazia Therapeutics profitable?
No. Kazia Therapeutics reported a net loss of A$20.7 million in fiscal 2025, a net profit margin of −49,290.5%; its operating margin was −33,850.0%.
What is Kazia Therapeutics's gross margin?
Kazia Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Kazia Therapeutics kept $100 after the direct cost of its products and services.
How much does Kazia Therapeutics spend on research and development?
Kazia Therapeutics spent A$7.3 million on research and development in fiscal 2025, 17,442.9% of revenue.
How fast is Kazia Therapeutics growing?
Revenue grew −46.8% a year on average over the last five fiscal years, from A$1.0 million to A$0.0 million.
When will Kazia Therapeutics report its next earnings?
Kazia Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does Kazia Therapeutics's fiscal year end?
Kazia Therapeutics's fiscal year ends in June. The latest annual report covers the year ended June 30, 2025 and was filed on November 7, 2025.